{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:40Z","timestamp":1793075620313,"version":"4.5.0"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      The benefits of baricitinib in coronavirus disease\u20102019 are inadequately defined. We performed a systematic review and meta\u2010analysis of studies of baricitinib to determine its clinical efficacy and adverse events in patients with COVID\u201019.\u00a0Databases were searched from their inception to September 5, 2021. The primary outcome was the coefficient of mortality. We also compared secondary indicators and adverse events between baricitinib treatment and placebo or other treatments.\u00a0Twelve studies of 3564 patients were included and assessed qualitatively (modified Jadad and Newcastle\u2013Ottawa Scale scores). Baricitinib effectively improved the mortality rate (relative risk of mortality = 0.56; 95% confidence interval: 0.46\u20130.69;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20092%), and this result was unchanged by subgroup analysis. Baricitinib improved intensive care unit admission, the requirement for invasive mechanical ventilation, and improved the oxygenation index. Data from these studies also showed that baricitinib slightly reduced the risk of adverse events. Regarding the choice of the drug dosage of baricitinib, the high\u2010dose group appeared to have additional benefits for clinical efficacy.\u00a0Our study shows that baricitinib may be a promising, safe, and effective anti\u2010severe acute respiratory syndrome\u2010coronavirus\u20102 drug candidate, with the advantages of low cost, easy production, and convenient storage.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jmv.27482","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T17:55:40Z","timestamp":1638294940000},"page":"1523-1534","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease\u20102019 (COVID\u201019): A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"94","author":[{"given":"Zhiwei","family":"Lin","sequence":"first","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health First Affiliated Hospital of Guangzhou Medical University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyi","family":"Niu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health First Affiliated Hospital of Guangzhou Medical University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health First Affiliated Hospital of Guangzhou Medical University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Qin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health First Affiliated Hospital of Guangzhou Medical University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Ding","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health First Affiliated Hospital of Guangzhou Medical University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqian","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health First Affiliated Hospital of Guangzhou Medical University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Weekly epidemiological update on COVID\u201019 \u2212 2021.https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104673"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107088"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.06.013"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S231558"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222944"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00331-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108027"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2021.100755"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01266-6"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20070147"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-45"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051263"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S66677"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060410"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa587"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141772"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06119-2"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1515\/med-2021-0010"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2021.05.009"},{"issue":"20","key":"e_1_2_10_25_1","first-page":"30271","article-title":"Experience with the use of baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID\u201019: a real\u2010world study","volume":"1699","author":"Rosas J","year":"2020","journal-title":"Reumatol Clin"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.06.052"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.017"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe4724"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa563"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2010.04.196"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.36469\/9744"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012697"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106749"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30304-4"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.49713"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00358-1"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.167"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.018"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30132-8"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508750"},{"issue":"4","key":"e_1_2_10_42_1","first-page":"343","article-title":"Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis","volume":"15","author":"Nesher G","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705054"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.049601"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.354"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-69"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27482","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.27482","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:16:51Z","timestamp":1793074611000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.27482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/jmv.27482"],"URL":"https:\/\/doi.org\/10.1002\/jmv.27482","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"2021-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}